Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

3.980 +0.150 (+3.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views
Following the market opening Wednesday, the Dow traded up 0.07% to 35,389.32 while the NASDAQ rose 0.17% to 15,045.45. The S&P also rose, gaining 0.14% to 4,492.57. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near
SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. 
Via InvestorPlace
Exposures Product Safety
Cassava Stock Plummets On Claims Of 'Data Manipulation' In Alzheimer's Testing
A shareholder firm called for the FDA to halt Cassava Sciences' studies in Alzheimer's disease, leading SAVA stock to plummet Wednesday. 
Via Investor's Business Daily
Exposures Product Safety
Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy
Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced... 
Via Benzinga
Why Cassava Sciences' Stock Is Getting Hammered Today
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 25.49% to $19.2 during Wednesday's pre-market session. The company's market cap stands at $242.7... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported... 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Cassava Sciences Has an Admirable Goal at Too High a Price
It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No. 
Via InvestorPlace
Cassava Sciences Receives FDA's Special Protocol Assessment For Alzheimer's Trials
Cassava Sciences Inc (NASDAQ: SAVA) announced an agreement with the FDA under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 trials for oral... 
Via Benzinga
Exposures Product Safety
Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth
With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits. 
Via InvestorPlace
Tread Carefully Before Pulling the Trigger on Cassava Sciences
While SAVA stock is intriguing based on the underlying Alzheimer’s treatment proposal, this market has an extremely high failure rate. 
Via InvestorPlace
Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk
SAVA stock has gone "to the moon" thanks to its Alzheimer treatment catalyst, but don't assume it's immune to a possible reversal. 
Via InvestorPlace
These Are the Top Reasons You Should Load Up on Cassava Sciences Stock
At the moment, there’s no cure for Alzheimer’s, but Cassava Sciences is working to wipe it out for good, making SAVA stock a buy here. 
Via InvestorPlace
With This Exciting Alzheimer’s Treatment, Cassava Sciences Stock Has Legs
Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock. 
Via InvestorPlace
Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug
Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock. 
Via InvestorPlace
Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?
Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results. 
Via The Motley Fool
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
How Much Should An Alzheimer's Drug Cost?
The answer is more complicated than you think. 
Via The Motley Fool
Navigating A Speculative Bubble
Invest while it inflates; protect before it pops. 
Via Talk Markets
Analyzing the Potential Risks of Cassava Sciences
Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far. 
Via InvestorPlace
Why Is Cassava Sciences' Stock So Volatile?
The stock is up 1,700% year to date. 
Via The Motley Fool
Cassava Sciences vs. Biogen
Who will emerge victorious in the race to help Alzheimer's patients? 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also rose, gaining 0.19% to 4,456.37. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate
Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function. 
Via The Motley Fool
Bring a Neck Brace When Trading Cassava Sciences
Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success. 
Via InvestorPlace
Why Shares of Cassava Sciences Fell 18.6% in July
The stock lost $75 a share in two days at the end of the month. 
Via The Motley Fool
What to Do After Cassava Sciences Dropped Off a Cliff
Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. 
Via InvestorPlace
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.